Literature DB >> 6818617

Differing mechanisms for leukotriene d4-induced bronchoconstriction in guinea pigs following intravenous and aerosol administration.

R Hamel, P Masson, A W Ford-Hutchinson, T R Jones, G Brunet, H Piechuta.   

Abstract

Leukotriene D4 (LTD4) when administered intravenously or by aerosol to guinea pigs produced changes in pulmonary mechanics including a decrease in dynamic compliance and an increase in pulmonary resistance. The effects of intravenous LTD4 (0.5 microgram kg-1) were short lived and abolished by pretreatment of the animal with either cyclooxygenase inhibitors, a thromboxane synthetase inhibitor (OKY 1555) or an SRS-A antagonist (FPL 55712). These findings suggest that bronchoconstriction produced by the intravenous infusion of LTD4 at 0.5 microgram kg-1 is due to the release of thromboxane A2. However, in animals treated with indomethacin, LTD4 at higher doses (greater than 0.8 microgram kg-1) still elicited a bronchoconstriction which could be blocked by FPL 55712. Nebulization of 0.1 - 1.0 microgram of LTD4 into the lung produced prolonged changes in pulmonary mechanics which were inhibited by FPL 55712 and were potentiated by indomethacin. LTD4, therefore, when administered by aerosol produced effects on the lung which were not mediated by cyclooxygenase products. Responses to nebulized rather than intravenous LTD4 in the guinea pig may more closely resemble those seen in human tissues.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6818617     DOI: 10.1016/0090-6980(82)90168-x

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  11 in total

1.  Bradykinin-induced plasma exudation in guinea-pig airways: involvement of platelet activating factor.

Authors:  D F Rogers; S Dijk; P J Barnes
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

2.  Increased secretion of glandular-kallikrein in the bronchial washings induced by intravenous injection of leukotriene C4 in guinea-pigs.

Authors:  H Y Jin; M Katori; M Majima; N Sunahara
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

3.  Renal vascular effects of leukotriene C4 in the isolated perfused kidney of the rat.

Authors:  J C Frölich; M Yoshizawa
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

4.  The role of arachidonic acid metabolites in local and systemic inflammatory processes.

Authors:  K F Austen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Studies on L-640,035: a novel antagonist of contractile prostanoids in the lung.

Authors:  R Carrier; E J Cragoe; D Ethier; A W Ford-Hutchinson; Y Girard; R A Hall; P Hamel; J Rokach; N N Share; C A Stone
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

6.  Involvement of capsaicin-sensitive afferent neurones in a vagal-dependent interaction between leukotriene D4 and histamine on bronchomotor tone.

Authors:  A G Stewart; D C Thompson; M R Fennessy
Journal:  Agents Actions       Date:  1984-12

7.  A 5-lipoxygenase inhibitor, FR110302, inhibits ozone-induced airway hyperresponsiveness in guinea pigs and dogs.

Authors:  M Asano; T Imai; H Inoue; T Masunaga; N Inamura; T Yatabe; J Hiroi; K Nakahara; Y Notsu; T Takishima
Journal:  Agents Actions       Date:  1993-03

8.  Leukotriene D4- and prostaglandin F2 alpha-induced airflow obstruction and airway plasma exudation in guinea-pig: role of thromboxane and its receptor.

Authors:  H Arakawa; J Lötvall; I Kawikova; C G Löfdahl; B E Skoogh
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

9.  Increased airways responsiveness to histamine induced by platelet activating factor in the guinea-pig: possible role of lipoxygenase metabolites.

Authors:  G P Anderson; H L White; M R Fennessy
Journal:  Agents Actions       Date:  1988-06

10.  The effect of indomethacin on the contractile response of the guinea-pig lung parenchymal strip to leukotrienes B4, C4, D4 and E4.

Authors:  K F Austen; E J Corey; J M Drazen; A G Leitch
Journal:  Br J Pharmacol       Date:  1983-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.